On March 12, 2026, Cadrenal Therapeutics, Inc. reported significant findings from pre-clinical research on its 12-LOX inhibitor, CAD-1005, indicating its potential to mitigate inflammation linked to obesity and Type 2 diabetes. This research builds on previous studies showing CAD-1005's effectiveness in delaying autoimmune diabetes onset in animal models.

Press Release distribution

National Press Distribution across U.S. Media. Direct Access to Key Decision Making Editors.